胡逸民博士（Dr.Yimin Hu）
凯臻生物医药(苏州)有限公司 联合创始人兼首席科学家
Chief Scientific Officer, Novacure Biosciences
胡逸民博士本科毕业于北京大学化学系，后赴美深造，就读于斯坦福大学并于2007年获得有机化学博士学位，并于哈佛大学进行了为期两年的博士后学习研究。归国后曾就职于葛兰素史克中国研发中心和罗氏创新中心，任药物化学高级研发人员。随后服务于恒瑞医药，任CMC执行总监。现参与创办凯臻生物，推动新型创新生物药的临床转化和开发。胡博士对创新药物的从发现到早期开发阶段的研发，以及产学研合作推动原创技术转化有丰富的成功经验。
Dr. Yimin Hu graduated from the Department of Chemistry at Peking University with a Bachelor’s degree. He pursued further studies in the United States, where he obtained Ph.D. degree at Stanford University and received postdoctoral training at Harvard University. After returning to China, he worked at the GSK and Roche as a senior researcher in medicinal chemistry. He later served at Hengrui Medicine as the Executive Director of CMC. Dr. Hu is currently co-founder and CSO for Novacure Biosciences, which is focusing on the development of breakthrough medicines based on innovative biomedical technologies. Dr. Hu has extensive experience and successful track records in the research and development of innovative medicines, as well as in promoting the clinical transformation of innovative technologies through academic-industry collaboration.
凯臻生物医药(苏州)有限公司 联合创始人兼首席科学家
Chief Scientific Officer, Novacure Biosciences
胡逸民博士本科毕业于北京大学化学系，后赴美深造，就读于斯坦福大学并于2007年获得有机化学博士学位，并于哈佛大学进行了为期两年的博士后学习研究。归国后曾就职于葛兰素史克中国研发中心和罗氏创新中心，任药物化学高级研发人员。随后服务于恒瑞医药，任CMC执行总监。现参与创办凯臻生物，推动新型创新生物药的临床转化和开发。胡博士对创新药物的从发现到早期开发阶段的研发，以及产学研合作推动原创技术转化有丰富的成功经验。
Dr. Yimin Hu graduated from the Department of Chemistry at Peking University with a Bachelor’s degree. He pursued further studies in the United States, where he obtained Ph.D. degree at Stanford University and received postdoctoral training at Harvard University. After returning to China, he worked at the GSK and Roche as a senior researcher in medicinal chemistry. He later served at Hengrui Medicine as the Executive Director of CMC. Dr. Hu is currently co-founder and CSO for Novacure Biosciences, which is focusing on the development of breakthrough medicines based on innovative biomedical technologies. Dr. Hu has extensive experience and successful track records in the research and development of innovative medicines, as well as in promoting the clinical transformation of innovative technologies through academic-industry collaboration.
